For personal use only
|
|
- Wilfrid Fletcher
- 5 years ago
- Views:
Transcription
1 2011 Annual General Meeting December 1, 2011 NASDAQ (UNIS) and ASX (UNS)
2 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward-looking statements are based on management s beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However you should not place undue reliance on any such forward looking statements as these are subject to risks and uncertainties. Please refer to our press releases and our SEC filings for more information regarding the use of forward looking statements. 2
3 Chairman s Welcome Jim Bosnjak OAM NASDAQ (UNIS) and ASX (UNS)
4 The Unilife Board of Directors Alan Shortall Executive Director and CEO since the founding of Unilife in
5 The Unilife Board of Directors Jeff Carter MApp. BFin Non Executive Director since 2006 CFO of Unilife from Chartered accountant with 25 years experience in financial and senior management roles in U.S. and Australia 5
6 The Unilife Board of Directors William Galle Non-Executive Director since 2008 Serves on Compensation and Nominating and Corporate Governance Committees More than 30 years experience in development and implementation of business growth and alternative investment strategies 6
7 The Unilife Board of Directors John Lund, CPA Non-Executive Director since 2009 Chair of Audit Committee Advising publicly listed companies on SEC reporting, M&A, and public accounting audit services since
8 The Unilife Board of Directors Mary Kate Wold, J.D. Non-Executive Director since 2010 Chair of the Strategic Partnerships Committee CEO of Church Pension Fund Group Previously SVP of Finance, Tax and Treasury at Wyeth 8
9 The Unilife Board of Directors Marc Firestone J.D. Non-Executive Director since 2010 Chair of Nominating and Corporate Governance Committee Executive Vide President and General Counsel for Kraft Foods 9
10 Agenda 1. Confirmation of Quorum 2. Resolutions Achievements and Outlook Alan Shortall 4. Questions 5. Confirmation of Results 6. Other Business 10
11 Confirmation of Quorum Unilife s quorum requirement is one-third of outstanding shares being represented either in person or by proxy Unilife has received at least 50% of the total outstanding shares entitled to vote are represented by person or by proxy. 11
12 CEO Presentation by Mr. Alan Shortall NASDAQ (UNIS) and ASX (UNS)
13 Our Position Redefining the market for advanced drug delivery systems Innovative, differentiated devices that can enable, enhance and extend the commercial success of injectable drugs and vaccines A rich portfolio of device technologies driven by unmet needs Our devices address the specific needs of the pharmaceutical customer, the therapeutic drug and the target patient Fully serving our customers with speed, agility and reliability Collaborations can originate during the clinical development of a pipeline drug and span its entire commercial lifecycle 13
14 Annual Highlights State-of-the-art facility in York, PA 14
15 Our Broad Operational Capabilities Enabling us to serve as an integrated partner for device innovation 15
16 Annual Highlights Continued to strengthen world-class team Management appointments this year include: Name Title Previous Employment Dr. Ramin Mojdeh COO BD (Pharma Systems & Product Development) Dr. Jack Kelley VP, Strategic Marketing BD, Medtronic Mike Ratigan VP, Commercial Development BD, Stryker Dr. Masoud Samandi VP, R&D BD Todd Smith VP, Integrated Supply Chain ConvaTec, Bristol Myers Squibb, Accenture Ian Hanson Director, Advanced Delivery Medtronic Diabetes Joe Runkle Senior Scientist Teleflex, West Pharma Alex Goraltchouk Snr Mngr, Advanced Drug Delivery Allergan Dr. Ashley Palmer Mngr, Advanced Drug Delivery BD Dr. Jyoti Gupta Mngr, Advanced Drug Delivery BD Dr. Gautam Shetty Mngr, Advanced Drug Delivery BD Dr. Molly Miller (BD) Mngr, Advanced Drug Delivery BD 16
17 Annual Highlights Completion of Unifill Syringe Industrialization Program 17
18 Annual Highlights Commenced Initial Supply of Unifill Syringe 18
19 Annual Highlights U.S. Rollout of Unitract 1mL syringes 19
20 Annual Highlights Diversified portfolio of Advanced Drug Delivery Systems 20
21 Annual Highlights Unifill Select 21
22 Annual Highlights Rita Auto-Injector 22
23 Annual Highlights AutoInfusor 23
24 Annual Highlights Novel Device for Targeted Organ Delivery First organ delivery device scheduled to enter into drug clinical trials with pharmaceutical partner in early 2012 Strong financial opportunity with U.S. and international prevalence rates for the target disease state being very high U.S. treatment costs exceeding $30 billion Device helps enable drug commercialization (avoids invasive surgery) Device-IP may extend lifecycle of combination products 24
25 Recent Capital Raising U.S. institutional investors purchased 8.25 million shares of Unilife common stock at a price of $4.35 per share 1 st U.S. offering over-subscribed, strong participation from bluechip accounts, healthcare dedicated and long-only funds 8.6% discount to UNIS s closing price of $ % of outstanding shares after this offering Net proceeds from offering are approximately $33.8 million 25
26 Recent Capital Raising Benefits of stronger cash position and balance sheet include: Strengthens negotiating position as Unilife begins to finalize partnership agreements with pharmaceutical companies Acceleration of R&D pipeline Expand workforce to support continued business growth Broadens and expands Unilife shareholder base 26
27 Summary All key elements of business strategy now in place Commercial rollout of Unifill proceeding exactly to plan Developed significant new pipeline products in direct response to unmet customer needs Discussions with multiple customers across multiple areas Attractive model with long-term contracts and strong margins Redefining the market for advanced drug delivery systems Differentiated products aimed at fastest-growing, highest-value sectors Becoming intertwined with $200 billion global injectable drug market 27
28 Resolutions 28
29 Item 1. Election of Directors For Withheld Item 1.1 Jim Bosnjak 23,743, % 2,666, % Item 1.2 Jeff Carter 25,166, % 1,243, % Item 1.3 William Galle 24,153, % 2,256, % Item 1.4 John Lund 24,610, % 1,799, % Item 1.5 Mary Kate Wold 26,056, % 353, % Item 1.6 Marc Firestone 26,055, % 354, % Item 1.7 Alan Shortall 24,496, % 914, % 29
30 Item 2. To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2012 Item 2. 32,098,125 (98.95%) For Against Abstain 216,238 (0.67%) 125,140 (0.38%) 30
31 Item 3. To consider and act on an advisory vote regarding the approval of compensation paid to certain executive officers Item 3. 22,188,789 (84.02%) For Against Abstain 3,535,099 (13.38%) 686,381 (2.60%) 31
32 Item 4. To consider and act on an advisory vote regarding the frequency of stockholder approval of the compensation of certain executive officers Item 4. 12,011,375 (47.90%) 1 Year 2 Years 3 Years 1,668,868 (6.65%) 11,396,460 (45.45%) 32
33 Item 5. For the purposes of ASX Listing Rule and for all other purposes, to approve the grant of up to 45,000 securities to Slavko James Joseph Bosnjak on the terms set out in the proxy statement Item 5.* 16,105,195 (73.31%) For Against Abstain 5,537,395 (25.20%) 327,057 (1.49%) * Excludes 4,440,622 shares voted on this proposal as required by ASX rules. 33
34 Item 6. For the purposes of ASX Listing Rule and for all other purposes, to approve the grant of up to 45,000 securities to Jeff Carter on the terms set out in the proxy statement Item 6.* 16,260,219 (74.01%) For Against Abstain 5,394,782 (24.56%) 314,646 (1.43%) * Excludes 4,440,622 shares voted on this proposal as required by ASX rules. 34
35 Item 7. For the purposes of ASX Listing Rule and for all other purposes, to approve the grant of up to 45,000 securities to William Galle on the terms set out in the proxy statement Item 7.* 16,222,434 (73.84%) For Against Abstain 5,437,066 (24.75%) 310,147 (1.41%) * Excludes 4,440,622 shares voted on this proposal as required by ASX rules. 35
36 Item 8. For the purposes of ASX Listing Rule and for all other purposes, to approve the grant of up to 45,000 securities to John Lund on the terms set out in the proxy statement Item 8.* 16,314,099 (74.26%) For Against Abstain 5,341,901 (24.31%) 313,647 (1.43%) * Excludes 4,440,622 shares voted on this proposal as required by ASX rules. 36
37 Item 9. For the purposes of ASX Listing Rule and for all other purposes, to approve the grant of up to 45,000 securities to Mary Katherine Wold on the terms set out in the proxy statement Item 9.* 16,328,849 (74.33%) For Against Abstain 5,325,651 (24.24%) 315,147 (1.43%) * Excludes 4,440,622 shares voted on this proposal as required by ASX rules. 37
38 Item 10. For the purposes of ASX Listing Rule and for all other purposes, to approve the grant of up to 45,000 securities to Marc Firestone on the terms set out in the proxy statement Item 10.* 16,272,275 (74.07%) For Against Abstain 5,382,225 (24.50%) 315,147 (1.43%) * Excludes 4,440,622 shares voted on this proposal as required by ASX rules. 38
39 Item 11. For the purposes of ASX Listing Rule and for all other purposes, to approve the grant of up to 1,916,000 securities to Alan D. Shortall on the terms set out in the proxy statement Item 11.* 15,183,097 (69.11%) For Against Abstain 6,354,190 (28.92%) 432,360 (1.97%) * Excludes 4,440,622 shares voted on this proposal as required by ASX rules. 39
40 Item 12. For the purposes of ASX Listing Rule 7.2 (Exception 9) and for all other purposes, to approve the 2009 Stock Incentive Plan, as proposed to be amended Item 12.* 15,852,588 (72.16%) For Against Abstain 5,518,225 (25.12%) 598,834 (2.72%) * Excludes 4,440,622 shares voted on this proposal as required by ASX rules. 40
41 Questions 41
42 Other Business 42
43 Meeting Close 43
2,500,000 Shares. Common Stock
Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-201841 Prospectus Supplement No. 15 to Prospectus dated February 26, 2015 2,500,000 Shares Common Stock This Prospectus Supplement No. 15
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationSeptember 18, 2017 Special Called Meeting of the U. T. System Board of Regents - Meeting of the Board
AGENDA SPECIAL CALLED TELEPHONE MEETING of THE UNIVERSITY OF TEXAS SYSTEM BOARD OF REGENTS September 18, 2017 Austin, Texas Page CONVENE THE BOARD IN OPEN SESSION TO RECESS TO EXECUTIVE SESSION PURSUANT
More informationBRUKER CORP FORM 8-K. (Current report filing) Filed 06/07/12 for the Period Ending 06/04/12
BRUKER CORP FORM 8-K (Current report filing) Filed 06/07/12 for the Period Ending 06/04/12 Address 40 MANNING RD BILLERICA, MA, 01821 Telephone 978663-3660 CIK 0001109354 Symbol BRKR SIC Code 3826 - Laboratory
More informationRick Legleiter Appointed Chief Executive Officer, Chairman Succession and Board Renewal Process
Universal Biosensors, Inc. ARBN 121 559 993 1 Corporate Avenue Rowville Victoria 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email info@universalbiosensors.com www.universalbiosensors.com
More informationTHE GOLDMAN SACHS GROUP, INC.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationNOTICE OF ANNUAL GENERAL MEETING. Thursday 30 March 2017 at am. H. Lundbeck A/S, Ottiliavej 9, DK-2500 Valby
TO THE SHAREHOLDERS OF H. LUNDBECK A/S NOTICE OF ANNUAL GENERAL MEETING Notice is hereby given of the annual general meeting of H. Lundbeck A/S to be held on: Thursday 30 March 2017 at 10.00 am The general
More informationFSIC FRANCHISE. Frequently asked questions
Frequently asked questions FSIC FRANCHISE 1. What are the details of the announced transaction? FS Investments ( FS ) and KKR Credit ( KKR ) announced an agreement to form a partnership to provide investment
More informationAccenture plc (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationTime Warner Inc. Report on Determination of Current Board Leadership Structure March 2015
Time Warner Inc. Report on Determination of Current Board Leadership Structure March 2015 This is the sixth annual report providing (i) a description of the Board of Directors policy and practices relating
More informationAstellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting
Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting Tokyo, Japan March 16, 2010 Astellas Pharma Inc. (TSE: 4503) today notified
More informationHBM Healthcare Investments Ltd Access to a Global and Diversified Private Equity Healthcare Portfolio
HBM Healthcare Investments Ltd Access to a Global and Diversified Private Equity Healthcare Portfolio SECA conference Zurich, 3 July 2013 Dr. Andreas Wicki, CEO HBM at a Glance SIX-listed investment company
More informationHalliburton and Baker Hughes Creating the leading oilfield services company
Halliburton and Baker Hughes Creating the leading oilfield services company Halliburton Investor Relations Contacts: Kelly Youngblood, Vice President Scott Danby, Manager 281.871.2688 or investors@halliburton.com
More informationINVESTOR PRESENTATION!
INVESTOR PRESENTATION ENHANCING HEALTH THROUGH CANNABIS SCIENCE WWW.EMERALDHEALTH.CA TSX.V:EMH TSX.V:EMH Disclaimer THE STATEMENTS MADE IN THIS PRESENTATION MAY INCLUDE FORWARD-LOOKING STATEMENTS REGARDING
More informationTHE GOLDMAN SACHS GROUP, INC.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationNOT FOR DISTRIBUTION IN THE USA,CANADA, JAPAN OR AUSTRALIA
Press release Baar, 28 January 2008 Attractive portfolio of investments in biotech and medical technology to be opened to the public HBM BioVentures announces further information of its planned IPO on
More informationALANCO TECHNOLOGIES INC
SECURITIES & EXCHANGE COMMISSION EDGAR FILING ALANCO TECHNOLOGIES INC Form: 8-K Date Filed: 2016-10-04 Corporate Issuer CIK: 98618 Copyright 2016, Issuer Direct Corporation. All Right Reserved. Distribution
More informationMara H. Rogers, Partner Norton Rose Fulbright
Mara H. Rogers Partner Norton Rose Fulbright US LLP New York T:+1 212 318 3206 F:+1 212 318 3400 mara.rogers@nortonrosefulbright.com vcard (+Outlook) Related services Corporate, M&A and securities Mergers
More informationIDEXX LABORATORIES, INC.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationWASHINGTON,D.C FORM8-K. CURRENTREPORT PursuanttoSection13or15(d)ofthe. Date of Report (Date of the earliest event reported): October29,2018
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION WASHINGTON,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)ofthe SecuritiesExchangeActof1934 Date of Report (Date of the earliest event reported):
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationCASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc. Your Strategic Drug Development Partner in China NASDAQ: CASI WWW.CASIPHARMACEUTIALS.COM Forward Looking Statements This presentation contains forward-looking statements within
More informationManagement to Host Conference Call at 8:30 a.m. ET today
Aclaris Therapeutics Reports Second Quarter 2016 Financial Results August 11, 2016 7:01 AM ET Management to Host Conference Call at 8:30 a.m. ET today MALVERN, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) -- (NASDAQ:ACRS),
More informationCATALENT PHARMA SOLUTIONS, INC.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationGenerex Announces Appointment of Executive Management Team
Generex Announces Appointment of Executive Management Team Company Integrates Latest Acquisition and Builds Corporate Foundation for Growth MIRAMAR, FL, November 15, 2018 -- Generex Biotechnology Corporation
More informationAcquisition of MST Medical Surgery Technologies Ltd:
Acquisition of MST Medical Surgery Technologies Ltd: Meaningfully Bolsters Senhance Platform Innovation to Further Advance Digital Laparoscopy September 24, 2018 2 FORWARD LOOKING STATEMENTS This presentation
More informationBLUEKNIGHT ENERGY PARTNERS, L.P.
BLUEKNIGHT ENERGY PARTNERS, L.P. FORM 8-K (Current report filing) Filed 09/19/12 for the Period Ending 09/13/12 Address 201 NW 10TH, SUITE 200 OKLAHOMA CITY, OK, 73103 Telephone (405) 278-6400 CIK 0001392091
More informationEnhancing Audit Quality and Transparency Supplement Additional information required by Article 13 of EU Regulation 537/2014
Enhancing Audit Quality and Transparency Supplement Additional information required by Article 13 of EU Regulation 537/2014 December 2017 kpmg.com Contents 1. Network arrangement 1 1.1 Legal structure
More informationFORM 8-K. MCORPCX, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 31, 2017 ( August31,2017) Date
More informationUNIVEST CORPORATION OF PENNSYLVANIA (Exact name of registrant as specified in its charter)
Section 1: 425 (8-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report
More informationANNUAL GENERAL MEETING OF SHAREHOLDERS AFFIMED N.V.
ANNUAL GENERAL MEETING OF SHAREHOLDERS AFFIMED N.V. to be held on Tuesday, June 19, 2018 at 15:00 hrs. (CET) at Amsterdam Marriott Hotel, Stadhouderskade 12, 1054 ES Amsterdam, the Netherlands Agenda 1
More informationALIBABA GROUP HOLDING LIMITED. c/o Alibaba Group Services Limited 26/F Tower One, Times Square 1 Matheson Street, Causeway Bay Hong Kong
ALIBABA GROUP HOLDING LIMITED c/o Alibaba Group Services Limited 26/F Tower One, Times Square 1 Matheson Street, Causeway Bay Hong Kong PROXY STATEMENT General The board of directors of Alibaba Group Holding
More informationUS GEOTHERMAL INC FORM 8-K. (Current report filing) Filed 09/15/11 for the Period Ending 09/15/11
US GEOTHERMAL INC FORM 8-K (Current report filing) Filed 09/15/11 for the Period Ending 09/15/11 Address 390 E. PARK CENTER BLVD, SUITE 250 BOISE, ID 83706 Telephone 208-424-1027 CIK 0001172136 Symbol
More informationQ Financial Results
Q3 2016 Financial Results November 29, 2016 DLS:TSXV Disclaimer Certain information in this presentation are forward-looking and relate to DealNet Capital anticipated financial position, business strategy,
More informationBOVIE MEDICAL CORPORATION
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationPage 1 of 5 LEGAL_1:
Acasti Pharma Business Update for the Fourth Quarter and Fiscal 2018 Patient enrollment in the two TRILOGY Phase 3 studies is progressing as planned: 463 patients enrolled and 41 patients randomized at
More informationPerspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond
Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond ACI Forum on Structuring, Negotiating and Managing Life Sciences Collaborations and Acquisitions February 28,
More informationDOWDUPONT INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (Date of earliest event
More informationKKR and FS Investments Form Strategic BDC Partnership Creates the Leading $18BN Alternative Lending Platform. December 2017
KKR and FS Investments Form Strategic BDC Partnership Creates the Leading $18BN Alternative Lending Platform December 2017 Strategic BDC Partnership Introduction On December 11, 2017, KKR and FS Investments
More informationJ.Crew Group, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationFS INVESTMENTS & KKR FORM STRATEGIC PARTNERSHIP. Combining FSIC & CCT platforms to create stockholder value
FS INVESTMENTS & KKR FORM STRATEGIC PARTNERSHIP Combining FSIC & CCT platforms to create stockholder value FS INVESTMENTS AND KKR TO ESTABLISH INDUSTRY-LEADING PARTNERSHIP FS Investments ( FS ) and KKR
More informationCeQur establishes Wales subsidiary
FOR IMMEDIATE RELEASE CeQur establishes Wales subsidiary -- Arthurian Life Sciences investment helps bring to market world s first three-day simple insulin infusion device for type 2 diabetes -- LUCERNE,
More informationFor personal use only
CFS RETAIL PROPERTY TRUST GROUP (CFX) Comprising: CFX Co Limited ABN 79 167 087 363 CFS Retail Property Trust 1 ARSN 090 150 280 Responsible Entity: Commonwealth Managed Investments Limited ABN 33 084
More informationLAW ENFORCEMENT ASSOCIATES CORP
LAW ENFORCEMENT ASSOCIATES CORP FORM 8-K (Current report filing) Filed 08/31/09 for the Period Ending 08/27/09 Address 2609 DISCOVERY DRIVE SUITE 125 RALEIGH, NC, 27616 Telephone (919) 872-6210 CIK 0001165921
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION. Form 8-K BMC STOCK HOLDINGS, INC.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event
More informationNAVISTAR INTERNATIONAL CORP
NAVISTAR INTERNATIONAL CORP FORM 8-K (Unscheduled Material Events) Filed 10/4/2005 For Period Ending 10/4/2005 Address 4201 WINFIELD ROAD WARRENVILLE, Illinois 60555 Telephone 630-753-5000 CIK 0000808450
More informationAXALTA COATING SYSTEMS LTD.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationMelco Crown Entertainment Limited
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness
More informationKOHLBERG CAPITAL CORPORATION. May 2007
KOHLBERG CAPITAL CORPORATION May 2007 Safe Harbor Statement Private Securities Litigation Reform Act of 1995 Forward Looking Information This presentation may include forward-looking statements. These
More information51JOB, INC. NOTICE OF ANNUAL GENERAL MEETING OF MEMBERS
51JOB, INC. NOTICE OF ANNUAL GENERAL MEETING OF MEMBERS NOTICE IS HEREBY GIVEN that the Annual General Meeting of Members (the Meeting ) of 51job, Inc., a Cayman Islands exempted company (the Company ),
More informationUBS Global Healthcare Services Conference February 14, 2006
UBS Global Healthcare Services Conference February 14, 2006 Forward-Looking Statements This presentation contains forward-looking statements that are subject to risks and uncertainties including, but not
More informationTo the Shareholders of Credit Suisse Group AG Invitation to the Annual General Meeting of Shareholders
To the Shareholders of Credit Suisse Group AG Invitation to the Annual General Meeting of Shareholders Friday, April 27, 2018, 10:30 a.m. Doors open at 9:00 a.m. Hallenstadion, Wallisellenstrasse 45 Zurich-Oerlikon
More informationKKR & Co. Inc. Reports Second Quarter 2018 Results
& Co. Inc. Reports Second Quarter 2018 Results NEW YORK, July 26, 2018 - KKR & Co. Inc. (NYSE: KKR) today reported its second quarter 2018 results. GAAP net income (loss) attributable to KKR & Co. L.P.
More informationThe general meeting will be held at the offices of the Company at: H. Lundbeck A/S, Ottiliavej 9, DK-2500 Valby
H. Lundbeck A/S Ottiliavej 9 Tel +45 36 30 13 11 E-mail investor@lundbeck.com DK-2500 Valby, Copenhagen www.lundbeck.com CVR number: 56759913 LEI code: 5493006R4KC2OI5D3470 Corporate Release Notice of
More informationDNB's 9th Annual Oil, Offshore & Shipping Conference Kristian Siem Chairman Subsea 7
DNB's 9th Annual Oil, Offshore & Shipping Conference Kristian Siem Chairman Subsea 7 1 Forward-looking statements Certain statements made in this announcement may include forward-looking statements. These
More informationElement Fleet Management Names Jay Forbes as Chief Executive Officer and Announces Intention to Refresh the Board with Four New Independent Directors
News Release Element Fleet Management Names Jay Forbes as Chief Executive Officer and Announces Intention to Refresh the Board with Four New Independent Directors TORONTO, Ontario, May 14, 2018 Element
More informationInvestor Presentation. June 2006
Investor Presentation June 2006 Forward-Looking Statements This presentation contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, the impact of
More informationCLIFFS NATURAL RESOURCES INC.
CLIFFS NATURAL RESOURCES INC. FORM 8-K (Current report filing) Filed 10/17/07 for the Period Ending 10/15/07 Address 200 PUBLIC SQUARE STE. 3300 CLEVELAND, OH 44114-2315 Telephone 216-694-5700 CIK 0000764065
More information51JOB, INC. NOTICE OF ANNUAL GENERAL MEETING OF MEMBERS
51JOB, INC. NOTICE OF ANNUAL GENERAL MEETING OF MEMBERS NOTICE IS HEREBY GIVEN that the Annual General Meeting of Members (the Meeting ) of 51job, Inc., a Cayman Islands exempted company, (the Company
More informationALLIANCE MEDIA HOLDINGS INC. NOTICE OF AN ANNUAL MEETING OF STOCKHOLDERS
ALLIANCE MEDIA HOLDINGS INC. NOTICE OF AN ANNUAL MEETING OF STOCKHOLDERS Notice is hereby given that the Annual Meeting of Stockholders of Alliance Media Holdings Inc. (the "Company") will be held at the
More informationWebinar: Perspectives on Board Evaluation Best Practices. March 1, 2018
Webinar: Perspectives on Board Evaluation Best Practices March 1, 2018 Webinar Housekeeping To ask a question during the webinar, please click the chat button. Questions submitted will be answered throughout
More informationGardner Denver Holdings, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event
More informationRobert DeVincenzi appointed as Redflex Holdings Chief Executive Officer as Graham Davie retires.
10 September 2012 Robert DeVincenzi appointed as Redflex Holdings Chief Executive Officer as Graham Davie retires. Redflex Holdings Limited (ASX:RDF) Chairman, Mr Max Findlay, announced today that Managing
More informationAnnual Report. Better Banking for Everyone
2017 Annual Report Better Banking for Everyone 2017 Board of Directors Jackie D. Cleghorn Chairman John A. Jones Vice Chairman Barry Brown Treasurer Kenneth L. Babbitt Secretary Mary S. Edenfield-Gibbs
More informationVIRTU FINANCIAL, INC.
VIRTU FINANCIAL, INC. FORM 8-K (Current report filing) Filed 04/12/16 for the Period Ending 04/08/16 Address 900 3RD AVENUE, 29TH FLOOR NEW YORK, NY 10022-0100 Telephone 212-418-0100 CIK 0001592386 Symbol
More informationMITHRA PHARMACEUTICALS ANNOUNCES ITS FIRST HALF 2016 FINANCIAL RESULTS AND OPERATIONAL PROGRESS
REGULATED INFORMATION MITHRA PHARMACEUTICALS ANNOUNCES ITS FIRST HALF 2016 FINANCIAL RESULTS AND OPERATIONAL PROGRESS Liège, Belgium 1 September 2016, 07h30 Mithra Pharmaceuticals, a leader in Women s
More informationFor personal use only. EBOS Group Limited. 94 th Annual Meeting. 19 October 2016
EBOS Group Limited 94 th Annual Meeting 19 October 2016 Important Information The information in this presentation was prepared by EBOS Group Ltd with due care and attention. However, the information is
More informationTHE PROGRESSIVE CORPORATION (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event
More informationGlobal Source Ventures, LLC Introduction. Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner
Global Source Ventures, LLC Introduction Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner Introduction to Global Source Ventures GSV provides seed capital to emerging companies with emphasis
More informationLIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationShareholders are invited to the 2018 Annual Meeting which is scheduled for 27 September 2018.
7 September 2018 Dear Shareholder 2018 Annual Meeting of Shareholders Shareholders are invited to the 2018 Annual Meeting which is scheduled for 27 September 2018. The details of the Annual Meeting are
More informationPRINCIPAL FINANCIAL GROUP, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More information51JOB, INC. NOTICE OF ANNUAL GENERAL MEETING OF MEMBERS
51JOB, INC. NOTICE OF ANNUAL GENERAL MEETING OF MEMBERS NOTICE IS HEREBY GIVEN that the Annual General Meeting of Members (the Meeting ) of 51job, Inc., a Cayman Islands exempted company (the Company ),
More informationDiversity drives diversity. From the boardroom to the C-suite
Diversity drives diversity From the boardroom to the C-suite Contents 2 Gender diversity accelerates board renewal and diversification. 4 Progress toward gender diversity on boards continues. 8 More women
More informationUGI Corporation (Exact name of Registrant as Specified in Its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationTextron Reports First Quarter 2016 Income from Continuing Operations of $0.55 per Share, up 19.6%; Reaffirms 2016 Financial Outlook
Textron Reports First Quarter 2016 Income Continuing Operations of $0.55 per Share, up 19.6%; Reaffirms 2016 Financial Outlook April 20, 2016 06:30 AM Eastern Daylight Time PROVIDENCE, R.I.--(BUSINESS
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K. Conformis, Inc. (Exact Name of Company as Specified in Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationConfirms 2013 Financial Guidance
Confirms 2013 Financial Guidance PROVIDENCE, R.I.--(BUSINESS WIRE)--Jul. 17, 2013-- Textron Inc. (NYSE: TXT) today reported second quarter 2013 income from continuing operations of $0.40 per share, compared
More informationJoint Press Release Acergy and Subsea 7 Agree to Combine
Joint Press Release Acergy and Subsea 7 Agree to Combine Creating a global leader in seabed-to-surface engineering and construction June 21, 2010 Acergy S.A. ( Acergy ) (NASDAQ-GS: ACGY; Oslo Stock Exchange:
More informationTextron Reports Second Quarter 2014 Income from Continuing Operations of $0.51 per Share, up 27.5%; Revenues up 23.5%
Textron Reports Second Quarter 2014 Income from Continuing Operations of $0.51 per Share, up 27.5%; Revenues up 23.5% 07/16/2014 PROVIDENCE, R.I.--(BUSINESS WIRE)-- Textron Inc. (NYSE: TXT) today reported
More informationGreg Nelson. Houston. Practice Areas. Admissions. Education. Partner, Tax Department
Greg Nelson Partner, Tax Department gregnelson@paulhastings.com Greg Nelson is office chair of the firm s Houston office and a partner in the Tax practice of Paul Hastings. He concentrates his practice
More informationFor personal use only
FASTBRICK ROBOTICS LIMITED (ASX:FBR) Investor Presentation October 2017 1 Contents 1. Fastbrick: A Robotics Technology Company 2. Our Strategic Pillars I. Hadrian X II. Global Partner III. Customer Discovery
More informationForward-Looking Statements and Non-GAAP Financial Measures
Forward-Looking Statements and Non-GAAP Financial Measures This presentation contains, and our other communications may contain, forward-looking statements within the meaning of Section 27A of the Securities
More informationGenerex Biotechnology Provides 2018 Year-End Summary & 2019 Plans
Generex Biotechnology Provides 2018 Year-End Summary & 2019 Plans - Acquisitions, Financing, Expansion Initiatives & Strategic Plans MIRAMAR, FL, January 22, 2019 - Generex Biotechnology Corporation (www.generex.com)
More informationSEADRILL LIMITED NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS SEPTEMBER 23, 2016
SEADRILL LIMITED NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS SEPTEMBER 23, 2016 NOTICE IS HEREBY given that the Annual General Meeting of Shareholders of Seadrill Limited (the Company ) will be held
More informationTRACY SEWARD CPA DECEMBER 2015 PAGE 1
TRACY SEWARD CPA Tracy Seward has over 20 years of financial accounting experience obtained through a diverse range of industry and senior management experience. He is a team leader devoted to creating
More informationForm 8-K. AXOGEN, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationCV SCIENCES, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationViking Advisory Group. Company Presentation September 2011
Viking Advisory Group Company Presentation September 2011 Viking Advisory Group Mission To offer value added, high quality services within the disciplines of financial management, accounting, legal, insurance,
More informationANNUAL GENERAL MEETING OF ARGENX SE EXPLANATORY NOTES
ANNUAL GENERAL MEETING OF ARGENX SE EXPLANATORY NOTES The following items on the agenda of the meeting shall be discussed and/or put to a vote. The numbers in the list correspond to the numbers on the
More informationMining Indaba 2010 Russell Ball Executive Vice President & CFO February 2, 2010 Cape Town, South Africa
Mining Indaba 2010 Russell Ball Executive Vice President & CFO February 2, 2010 Cape Town, South Africa Newmont Mining Corporation February 2, 2010 Mining Indaba 1 Cautionary Statement This presentation
More informationMedicines Manufacturing in the UK 2017
Medicines Manufacturing in the UK 2017 Moderator: Magda Papadaki, PhD Head of Manufacturing Innovation The Association of the British Pharmaceutical Industry Medicines Manufacturing Industry Partnership
More informationJG SUMMIT HOLDINGS, INC.
JG SUMMIT HOLDINGS, INC. MINUTES OF THE ANNUAL MEETING OF STOCKHOLDERS JUNE 27, 2017, 5:00 P.M. Crowne Plaza Manila Galleria, Quezon City, Metro Manila, Philippines Directors and Advisory Board Members
More informationMAXWELL TECHNOLOGIES, INC. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More information2006 ANNUAL SHAREHOLDER MEETING April 27, 2006
2006 ANNUAL SHAREHOLDER MEETING April 27, 2006 Good morning. It s ten o clock. My name is Mark McAndrew. I m Chairman of the Board and Chief Executive Officer of Torchmark, and welcome to Torchmark s 25
More informationChanges to the IPO Process
Changes to the IPO Process Part 1 of the Impact of the JOBS Act on Private Equity Podcast Series July 2, 2012 JOBS Act Podcast Series The Jumpstart Our Business Startups Act (or JOBS Act ) became law on
More informationHY2015. Disciplined performance management. Redefining the future for people and places 1. Attractive growth fundamentals & opportunities
HY2015 Attractive growth fundamentals & opportunities Disciplined performance management Redefining the future for people and places 1 Overview Resilient underlying performance HY2015 Headline EPS 31.3p
More informationErratum to the Press Release 2017 annual results - NRJ Group. dated March 15, 2018
Paris, March 20, 2018 5:45 pm Erratum to the Press Release 2017 annual results - NRJ Group dated March 15, 2018 An editorial error was made in the press release dated March 15, 2018 (English version only)
More informationUnion Pacific Corporation
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More information